Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 07, 2023 -- Fulcrum Therapeutics, Inc.® , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases,...